CDT Equity Inc. (CDT) - Form 10-Q Summary
Business Context and Reporting Period
Reporting Period: Quarterly period ended June 30, 2026.
Company Overview: CDT Equity Inc. is a data-driven pharmaceutical development and digital asset treasury management company. It focuses on identifying and advancing high-potential therapeutic assets using AI, solid-form chemistry, and asset repositioning. The company operates with a lean, asset-agnostic model, avoiding late-stage clinical trials in favor of licensing and commercialization partnerships.
Capital Structure: As of August 12, 2026, there were 786,670 shares of common stock issued and outstanding. The company has undergone five reverse stock splits between January 2025 and July 2026, with historical data retroactively adjusted.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8,704) | $(10,781) |
| Operating Loss | $(6,658) | $(8,568) |
| Research & Development Expenses | $1,080 | $2,776 |
| General & Administrative Expenses | $5,578 | $5,792 |
| Cash and Cash Equivalents (End of Period) | $747 | $3,332 |
| Net Cash Used in Operating Activities | $(2,438) | $(6,509) |
| Total Assets | $126,708 | $5,650 |
| Total Liabilities | $23,615 | $12,820 |
| Stockholders' Equity | $103,093 | $(7,170) |
Note: The significant increase in Total Assets and Equity is primarily driven by a $122.8 million equity method investment in Sarborg Limited.
Material Changes vs. Prior Period
- Investment in Sarborg: In February 2026, the company acquired a 20% equity interest in Sarborg Limited for total consideration of $123 million (stock, pre-funded warrants, and deferred cash). This investment is recorded at fair value under the equity method, significantly altering the balance sheet composition.
- Operating Expenses: R&D expenses decreased by 61% ($1.7 million) compared to the prior six-month period, primarily due to reduced expenses related to Sarborg service agreements. G&A expenses decreased slightly by 4%.
- Debt Restructuring: The company issued a $2.0 million senior secured convertible promissory note to J.J. Astor & Co. in June 2026. Subsequent amendments in July and August 2026 increased the principal balance to approximately $2.5 million and adjusted repayment terms due to missed payments.
- Liquidity: Cash and cash equivalents declined from $1.5 million at year-end 2025 to $0.7 million at June 30, 2026.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for at least 12 months. The company has an accumulated deficit of $77.0 million and insufficient cash to fund its current business plan without additional funding.
- Funding Strategy: The company relies on an At-The-Market (ATM) offering program (Sales Agreement) with approximately $73.6 million in available funds (subject to reduction) and potential debt financing. There is no assurance that funding will be available when needed.
- Legal Contingencies:
- Strand Litigation: A judgment of approximately $9.6 million was finalized against a subsidiary (CPL) in December 2025. Although CPL was sold to a related party, the liability remains on the consolidated balance sheet due to lack of isolation. The company is vigorously defending against enforcement.
- IP Dispute: St George Street Capital has challenged the company's ownership of the AZD 1656 co-crystal patent. The company believes there are no financial implications and has not accrued a loss contingency.
- Controls and Procedures: Disclosure controls and procedures were deemed not effective due to material weaknesses previously identified and not yet remediated.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to access the $73.6 million ATM facility and secure additional debt financing to cover the $21.0 million working capital requirement for the next 12 months.
- Sarborg Investment: Review the valuation methodology and impairment testing for the $122.8 million equity method investment in Sarborg, a related party.
- J.J. Astor Note: Monitor the repayment schedule and potential default risks associated with the amended $2.5 million convertible note, including the requirement to generate $115,000 in weekly ATM proceeds.
- Strand Liability: Assess the risk of the $9.6 million litigation liability being enforced against the parent company despite the sale of the subsidiary.
- Internal Controls: Evaluate the timeline and plan for remediating the material weaknesses in internal controls over financial reporting.